Neuronanomedicine for Alzheimer's and Parkinson's disease: Current progress and a guide to improve clinical translation.

Boyton, I; Valenzuela, SM; Collins-Praino, LE; Care, A

Neuronanomedicine for Alzheimer's and Parkinson's disease: Current progress and a guide to improve clinical translation.

Boyton, I Valenzuela, SM Collins-Praino, LE Care, A

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Brain Behav Immun, 2023, pp. S0889-1591(23)00337-9
Issue Date:: 2023-11-13

Closed Access

	Filename	Description	Size
	Boyton. Neuronanomedicine.2023.pdf	Published version	5.11 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Boyton, I
dc.contributor.author	Valenzuela, SM
dc.contributor.author	Collins-Praino, LE
dc.contributor.author	Care, A https://orcid.org/0000-0002-0035-7961
dc.date.accessioned	2023-12-05T04:40:54Z
dc.date.available	2023-11-08
dc.date.available	2023-12-05T04:40:54Z
dc.date.issued	2023-11-13
dc.identifier.citation	Brain Behav Immun, 2023, pp. S0889-1591(23)00337-9
dc.identifier.issn	0889-1591
dc.identifier.issn	1090-2139
dc.identifier.uri	http://hdl.handle.net/10453/173709
dc.description.abstract	Neuronanomedicine is an emerging multidisciplinary field that aims to create innovative nanotechnologies to treat major neurodegenerative disorders, such as Alzheimer's (AD) and Parkinson's disease (PD). A key component of neuronanomedicine are nanoparticles, which can improve drug properties and demonstrate enhanced safety and delivery across the blood brain barrier, a major improvement on existing therapeutic approaches. In this review, we critically analyze the latest nanoparticle-based strategies to modify underlying disease pathology to slow or halt AD/PD progression. We find that a major roadblock for neuronanomedicine translation to date is a poor understanding of how nanoparticles interact with biological systems (i.e., bio-nano interactions), which is partly due to inconsistent reporting in published works. Accordingly, this review makes a set of specific recommendations to help guide researchers to harness the unique properties of nanoparticles and thus realise breakthrough treatments for AD/PD.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Brain Behav Immun
dc.relation.isbasedon	10.1016/j.bbi.2023.11.004
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1107 Immunology, 1109 Neurosciences, 1701 Psychology
dc.subject.classification	Neurology & Neurosurgery
dc.subject.classification	3204 Immunology
dc.subject.classification	3209 Neurosciences
dc.subject.classification	5202 Biological psychology
dc.title	Neuronanomedicine for Alzheimer's and Parkinson's disease: Current progress and a guide to improve clinical translation.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	1107 Immunology
utslib.for	1109 Neurosciences
utslib.for	1701 Psychology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access	*
dc.date.updated	2023-12-05T04:40:52Z
pubs.publication-status	Published online

Abstract:

Neuronanomedicine is an emerging multidisciplinary field that aims to create innovative nanotechnologies to treat major neurodegenerative disorders, such as Alzheimer's (AD) and Parkinson's disease (PD). A key component of neuronanomedicine are nanoparticles, which can improve drug properties and demonstrate enhanced safety and delivery across the blood brain barrier, a major improvement on existing therapeutic approaches. In this review, we critically analyze the latest nanoparticle-based strategies to modify underlying disease pathology to slow or halt AD/PD progression. We find that a major roadblock for neuronanomedicine translation to date is a poor understanding of how nanoparticles interact with biological systems (i.e., bio-nano interactions), which is partly due to inconsistent reporting in published works. Accordingly, this review makes a set of specific recommendations to help guide researchers to harness the unique properties of nanoparticles and thus realise breakthrough treatments for AD/PD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173709